Hennion & Walsh Asset Management’s Verona Pharma VRNA Stock Holding History

Hennion & Walsh Asset Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-185,819	Closed	-$19.8M	–	1002
2025 Q3	$19.8M	Sell	185,819 -12,695	-6%	-$1.33M	0.72%	17
2025 Q2	$18.8M	Sell	198,514 -959	-0.5%	-$71K	0.76%	14
2025 Q1	$12.7M	Buy	199,473 +5,766	+3%	+$345K	0.56%	26
2024 Q4	$9M	Buy	193,707 +37,872	+24%	+$1.42M	0.41%	41
2024 Q3	$4.48M	Buy	155,835 +20,206	+15%	+$497K	0.21%	113
2024 Q2	$1.96M	Buy	135,629 +68,264	+101%	+$997K	0.1%	252
2024 Q1	$1.08M	Buy	67,365 +28,071	+71%	+$485K	0.06%	400
2023 Q4	$781K	Buy	+39,294	New	+$580K	0.04%	467

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Hennion & Walsh Asset Management's VRNA Position: Q4 2025 in Review

Hennion & Walsh Asset Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 185,819 shares — an estimated $19.8M sold.

Hennion & Walsh Asset Management first reported a position in VRNA in Q4 2023 and held it in 8 quarters. The position peaked at $19.8M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Hennion & Walsh Asset Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Hennion & Walsh Asset Management sold 185,819 Verona Pharma shares in Q4 2025, an estimated $19.8M.
Hennion & Walsh Asset Management first reported a position in Verona Pharma in Q4 2023 and held it in 8 quarters.
Hennion & Walsh Asset Management's Verona Pharma position peaked at $19.8M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2025, filed 14 Jan 2026.